VIRI Profile
Virios Therapeutics, Inc. is a biotechnology company in the development stage, specializing in creating antiviral therapies aimed at treating diseases linked to viral-triggered abnormal immune responses.
The company's flagship development candidate, IMC-1, is a fixed-dose combination therapy comprising famciclovir and celecoxib. This candidate is being evaluated for its potential to treat fibromyalgia, a chronic condition characterized by widespread pain, fatigue, and other symptoms. IMC-1 represents a novel approach by targeting the underlying viral mechanisms believed to contribute to fibromyalgia.
In addition to IMC-1, Virios Therapeutics is advancing IMC-2, another combination therapy that merges valacyclovir with celecoxib. IMC-2 is designed to address the multifaceted symptoms associated with long COVID, including fatigue, sleep disturbances, attention issues, pain, autonomic dysfunction, and anxiety. This therapy aims to provide a comprehensive solution for managing the prolonged and complex manifestations of COVID-19.
Originally founded as Virios Therapeutics, LLC in 2012, the company rebranded to Virios Therapeutics, Inc. in December 2020. Headquartered in Alpharetta, Georgia, Virios Therapeutics continues to focus on innovative antiviral treatments and aims to leverage its unique approach to address significant unmet medical needs. The company’s commitment to developing therapies that target viral-induced immune dysfunction underscores its strategic vision in the biotechnology sector.
|
